USC – Technology IP Office and Promising Biotechnologies.

USC – Technology

IP Office and Promising Biotechnologies

USC – Technology

Introduction

Chad Hardaway, P.E., MBA, JDSenior Licensing AssociateIntellectual Property OfficeUniversity of South CarolinaResearch FoundationLife and Physical Sciences

USC – Technology

New Faculty

New Facilities

Research Focus

Strategic Partnerships

Enhanced Academic Reputation

USC Future Keys to Success

Enhanced Economic Development

USC – Technology

Environmental

Research

BiomedicalSciences

Next Energy

Nanotechnology

Focus Current Research Themes

USC – Technology

Research Centers of Economic Excellence Funded Proposals

• Brain Imaging – $5 million – USC/MUSC

• Regenerative Medicine– $6 million– MUSC/Clemson/USC

• Translational Cancer Therapeutics – $5 million– MUSC/USC

• Drug Discovery in Cancer– $5 million– MUSC/USC

• Vision Science– $4.5 million– MUSC/USC

USC – Technology

Recent Newspaper Articles

USC – Technology

Horizon Center Plans

UniversityPrivate

USC – Technology

The Vision

USC – Technology

NSF Expenditures DataFY02 (latest available)

Institution & Ranking

Total $ Federal Govt.

State & Local Govt.

Industry Institutional Funds

Other

Clemson (87)

134,840

47,174 19,669 12,035 55,444 518

MUSC (90)

132,030

75,803 948 9,939 33,710 11,630

USC (95)

123,108

53,403 5,180 5,050 54,541 4,934

USC – Technology

Intellectual Property Data Activity FY04 FY05 %

Change

Invention Disclosures Received

51 64 25%

Patent Apps. Filed 10 12 20%

Provisional Patent Apps. 20 47 135%

Licenses/Options Signed 10 16 60%

Start-up Companies Formed

2 4 100%

USC – Technology

Intellectual Property Data Activity FY04 FY05 %

Change

Licensing Income Received

$200K $305K 53%

Licensing-related Research Funding

n/a $401K n/a

Total Income from Licensing

$201K $709K 249%

CDA’s 71 120 69%

MTA’s 18 37 105%

USC – Technology

SBIR/STTR Awards

Fiscal Year 2004 2005

Executed Awards

3 9

Executed Awards - $

$

$87,338 $600,484

USC – Technology

USC – Licensing Approaches

Straight Buy-out

Straight Equity

USC has done deals at both

extremes and at all points in between!

$$$$ %%%%

USC – Technology

Promising Biotechnologies

• Featured Technologies

• M3A Novel Antibiotic Compound

• Novel Hypertension Compound

• PLEOF Copolymer Networks as a Bioresorbable Scaffold for Tissue Regeneration

• Fluorescent Bioconjugation

• Hernia repair with novel collagen scaffolds

• Additional Technologies

• PAD Inhibitors for treatment of Rheumatoid Arthritis

• Novel Methoxyestradiol Compounds

• Novel Resuscitative Fluid for Trauma Patients

• Cold Sterilization

USC – Technology

M3A Novel Antibiotic Compound

OVERVIEW

Novel AntibioticBroad spectrum activity

Effective against resistant strainsDrug resistance is an ongoing problem

STATUS

Culture process developedInitial efficacy & safety data

US patent issued

DEVELOPMENT NEEDS

Isolate & identify compound(s)Develop production processAdditional efficacy testingPreclinical safety testing

USC – Technology

Novel Hypertension Compound

OVERVIEW

Effective for treatment of cardio conditions and spasmodic asthma

Dual Action – L-type Ca2+ antagonistcAMP PDE inhibitor

Slows rate without blocking antrioventricular conduction

STATUS

In vivo testing on carotid arterial blood pressure

Preliminary in vivo safety dataIn vitro testing on cardio and smooth

muscle effectsUS patent pending

DEVELOPMENT NEEDS

Additional efficacy testingPreclinical safety testingDevelopment to market

Time(min)

0 100 200 300 400 500 600 700

BP

(mm

Hg

)

20

40

60

80

100

120

140

160

180

MAP SBP DBP PP

USC – Technology

PLEOF Copolymer Networks as a Bioresorbable Scaffold for Tissue Regeneration

OVERVIEW

40 M affected by arthritis in US. 1 M patients undergo surgery for osteoarthritis of knee, hip, shoulder, and spine every year.

These PLEOF compounds can be used to repair/ replace damaged bone, cartilage, etc.

STATUS

Preliminary in vitro and in vivo data collectedCan be produced in large quantitiesUS Patent Pending

DEVELOPMENT NEEDS

• Additional efficacy testing• Preclinical safety testing• Short FDA approval route as device• Develop to Market

SpinalFracture

Injection of Composite

USC – Technology

Process for linking nanoparticles Fluorescent signal created with linkage

Wide applications including pharmaceuticals, diagnostics, and

various other nanotech uses

OVERVIEW

DEVELOPMENT STATUS DEVELOPMENT NEED

Lab testing complete Variety of reactions tested

Hundreds of novel dyes madePatent pending

Target market analysisFinancial & business analysis

Validation of target applications

Fluorescent Bioconjugation

+Cu (I) N

NN

N3

prelinkers

biomolecules

"switch"

highly fluorescent linkage

profluorophore

USC – Technology

Hernia repair with novel collagen scaffolds

OVERVIEW

Currently there is no wide acceptance of Engineered soft tissues and no gold standard for repair of ventral hernias. This technology offers a tissue engineered repair system that can rapidly vascularize to repair ventral hernial defects as well as other defects.

STATUS

Repaired over 30 rat ventral hernias Demonstrated the control release technology causes rapid neovascularization Demonstrated differentiated skeletal muscle within the repair site.

DEVELOPMENT NEEDS

•Establish the technology to obtain full thickness muscular repair

•Transfer technology to large animal studies

•Initiate the FDA approval process.

Before

After

USC – Technology

IP Office Contact InformationLisa Rooney, JD, [email protected]

Chad Hardaway, P.E., MBA., JD Senior Licensing Associate803-777-4031 [email protected]

USC Research FoundationIntellectual Property Office901 Sumter Street, Suite 514Columbia, SC 29208

Web Site http://ip.research.sc.edu